A study of patients with aggressive multiple sclerosis at disease onset
Ulrike W Kaunzner,1 Gaurav Kumar,2 Gulce Askin,3 Susan A Gauthier,1 Nancy N Nealon,1 Timothy Vartanian,1 Jai S Perumal1 1Judit Jaffe Multiple Sclerosis Center, Weill-Cornell Medical College, New York City, NY, 2Department of Cell Biology and Neuroscience, Rutgers University, New Brunswick, NJ, 3Ins...
Guardado en:
Autores principales: | , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/40b89627044949a795a4d190d375434f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sumario: | Ulrike W Kaunzner,1 Gaurav Kumar,2 Gulce Askin,3 Susan A Gauthier,1 Nancy N Nealon,1 Timothy Vartanian,1 Jai S Perumal1 1Judit Jaffe Multiple Sclerosis Center, Weill-Cornell Medical College, New York City, NY, 2Department of Cell Biology and Neuroscience, Rutgers University, New Brunswick, NJ, 3Institute for Biostatistics and Epidemiology, Weill-Cornell Medical College, New York City, NY, USA Objective: Identify aggressive onset multiple sclerosis (AOMS) and describe its clinical course.Methods: AOMS patients were identified from a multiple sclerosis (MS) database based on a set of criteria. The subsequent clinical course of AOMS patients was then reviewed with the goal of potentially identifying the best approaches to manage these patients.Results: Fifty-eight of 783 (7.4%) patients in the MS database met the criteria for AOMS, and 43 patients who had complete data for the duration of their follow-up were included in the subsequent analysis. The mean duration of the follow-up was 54 months. Thirty-five patients (81%) were started on a conventional first-line agent (injectable therapies for MS). Only two of these 35 patients (5.7%) had no evidence of disease activity. Twenty-two of 35 patients suffering from refractory disease were switched to a more aggressive treatment (natalizumab, rituximab, alemtuzumab, cyclophosphamide). Eight patients were started on aggressive treatment as their initial therapy, and seven of these eight (87.5%) patients showed no evidence of disease activity.Conclusion: With recognition of the crucial significance of early optimal treatment during the potential window of opportunity for best long-term outcomes, we describe AOMS within 1 year of disease onset and discuss possible treatment considerations for these patients. Keywords: aggressive multiple sclerosis, algorithm, treatment course, database, retrospective analysis |
---|